Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL (NCT07493330) | Clinical Trial Compass
Not Yet RecruitingPhase 1/2
Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL
86 participantsStarted 2026-03-23
Plain-language summary
To evaluate the safety and efficacy of Zeprumetostat-based combination therapy, selected according to genotyping results, in patients with primary refractory peripheral T-cell lymphoma (PTCL).
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Exclusion criteria
. Requires continuous treatment with strong or moderate CYP3A inhibitors or CYP3A inducers
. Has multiple factors affecting oral medication administration (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.);
. Has a history of psychoactive substance abuse that cannot be discontinued
. Has any severe and/or uncontrolled disease.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial combines an EZH2 inhibitor with other targeted agents chosen based on a patient's specific genetic profile — can you walk me through what genotype testing would need to happen first, and whether my tumor has already been tested for the mutations this trial is targeting?
2Since this is a Phase 1/Phase 2 trial and Phase 1 is still focused on identifying dose-limiting toxicities, what does that mean for how much is currently known about the safety of this combination, and how would that weigh against other options for my situation?
3The trial is listed as 'not yet recruiting' — given how quickly refractory PTCL can progress, is the expected timeline for this trial to open realistic for my situation, or should we be prioritizing treatments that are available right now?
4For the Phase 2 portion, the main thing being measured is overall response rate — can you help me understand what that means in practical terms, and how it compares to the response rates I might expect from standard salvage therapies?
5Because this trial is specifically for primary refractory PTCL, does my treatment history actually fit that definition, and if I were to try another therapy first, would that potentially affect my eligibility down the road if the trial opens?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Summary of DLT events (Phase Ib)
Timeframe: At the end of Cycle 1 (each cycle is 28 days)
2
Overall response rate (Phase Ⅱ)
Timeframe: At the end of Cycle 3 (each cycle is 28 days)